Ravanshad et al. (37) designed a single arm randomized trial for obese patients with NAFLD.A low calorie LFD (FAT: 25–30%, CHO: 55–60%) for 6 weeks resulted in decreased body weight and mean serum ALP, ALT, AST levels. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.